Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Blood (2023) 142 (23): 1960–1971.

https://doi.org/10.1182/blood.2023020301

Published: 2023

Includes: Supplemental data

Journal Articles

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Blood (2022) 140 (Supplement 1): 2326–2328.

https://doi.org/10.1182/blood-2022-160386

Published: 2022

Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Blood (2022) 140 (Supplement 1): 3753–3755.

https://doi.org/10.1182/blood-2022-157729

Published: 2022

Journal Articles

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Blood (2022) 140 (Supplement 1): 3341–3343.

https://doi.org/10.1182/blood-2022-167837

Published: 2022

Journal Articles

High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study

Chong Chyn Chua, Natasha S Anstee, Anoop Kumar Enjeti, Devendra Hiwase, Paula Marlton, Ashish Bajel, Shuh Ying Tan, Edward S. Morris, Chun-Kei-Kris Ma, Carolyn Grove, Julian Cooney, Ashanka Beligaswatte, Rachel M Koldej, Stephen B Ting, Travis Perera, Amanda Johnston, John Reynolds, David Ritchie, Andrew H Wei

Blood (2022) 140 (Supplement 1): 3362–3364.

https://doi.org/10.1182/blood-2022-163084

Published: 2022

Journal Articles

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

Daniel J. DeAngelo, Brian A. Jonas, Jane L. Liesveld, Dale L. Bixby, Anjali S. Advani, Paula Marlton, John L. Magnani, Helen M. Thackray, Eric J. Feldman, Michael E. O’Dwyer, Pamela S. Becker

Blood (2022) 139 (8): 1135–1146.

https://doi.org/10.1182/blood.2021010721

Published: 2022

Includes: Supplemental data

Journal Articles

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2021-147937

Published: 2021

Journal Articles

An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia

Chong Chyn Chua, John Reynolds, Anoop Kumar Enjeti, Devendra Hiwase, Paula Marlton, Ashish Bajel, Shuh Ying Tan, Edward S. Morris, Chun-Kei-Kris Ma, Carolyn Grove, Julian Cooney, Ashanka Beligaswatte, Natasha Anstee, Stephen B Ting, Travis Perera, Amanda Johnston, David Ritchie, Andrew H. Wei

Blood (2021) 138 (Supplement 1): 368.

https://doi.org/10.1182/blood-2021-149488

Published: 2021

Journal Articles

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Natasha S Anstee, PhD, Giovanna Pomilio, Mark Levis, MD PhD, Sarah MacRaild, Michael Murray, PhD DSc, Tristan Rawling, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, James D'Rozario, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Adam Ivey, BSc, MSc, PhD, Doen Ming Ong, MBBS, Andrew W Roberts, MBBS, Andrew H Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-141711

Published: 2020

Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-137334

Published: 2020

Journal Articles

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Giuseppe Gritti, MD PhD, Paula Marlton, MBBS FRACP FRCPA, Tycel J. Phillips, MD, Christopher Arthur, Rajat Bannerji, MDPhD, Paolo Corradini, Anna Johnston, John F. Seymour, Sam Yuen, MBBS, FRACP, FRCPA, Jamie Hirata, Lisa Musick, Sourish Saha, Brandon Croft, Christopher Flowers, MDMS

Blood (2020) 136 (Supplement 1): 45–47.

https://doi.org/10.1182/blood-2020-136361

Published: 2020

Journal Articles

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Blood (2020) 136 (18): 2038–2050.

https://doi.org/10.1182/blood.2020006844

Published: 2020

Includes: Supplemental data

Journal Articles

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Munoz, Alessandra Tedeschi, Andrew W. Roberts, John F. Seymour, Siminder Kaur Atwal, Yiling Yu, William Novotny, Eric Holmgren, Ziwen Tan, James D. Hilger, Jane Huang, Constantine S. Tam

Blood (2020) 136 (18): 2027–2037.

https://doi.org/10.1182/blood.2020006449

Published: 2020

Includes: Supplemental data

Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2690.

https://doi.org/10.1182/blood-2019-123744

Published: 2019

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Blood (2019) 134 (11): 851–859.

https://doi.org/10.1182/blood.2019001160

Published: 2019

Includes: Supplemental data

Journal Articles

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

Daniel J. DeAngelo, MD, Brian A. Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD PhD, Anjali S. Advani, MD, Paula Marlton, Michael E O'Dwyer, MD, William E Fogler, PhD, Curt D Wolfgang, PhD, John L Magnani, PhD, Helen M Thackray, MD, Pamela S. Becker, MD

Blood (2018) 132 (Supplement 1): 331.

https://doi.org/10.1182/blood-2018-99-114286

Published: 2018

Journal Articles

Vascular E-Selectin Acts As a Gatekeeper Inducing Commitment and Loss of Self-Renewal in HSC Transmigrating through the Marrow Vasculature

Ingrid G Winkler, PhD, Valerie Barbier, Masters, Jessica Lowe, BSc(Hons), Joshua Tay, PhD, John L Magnani, PhD, Paula Marlton, Anthony K Mills, FRACP, FRCPA, MBBS, Andrew Perkins, MBBS, PhD FRCPA, FRACP, Corrine E Fiveash, BSc(Hons), Johanna M Erbani, PhDstudent, Jean-Pierre Levesque, PhD

Blood (2018) 132 (Supplement 1): 4552.

https://doi.org/10.1182/blood-2018-99-120376

Published: 2018

Journal Articles

Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

Richard Greil, MD, Graeme Fraser, Brian Leber, MD, Reinhard Marks, Giulia Quaresmini, Jan Moritz Middeke, Gianpietro Semenzato, William Schary, Michelle Boyer, Madlaina Breuleux, PhD DAS, Noelle Crompton, Kathryn Humphrey, Paula Marlton

Blood (2018) 132 (Supplement 1): 5548.

https://doi.org/10.1182/blood-2018-99-118148

Published: 2018

NARROW

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

Vascular E-Selectin Acts As a Gatekeeper Inducing Commitment and Loss of Self-Renewal in HSC Transmigrating through the Marrow Vasculature

Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only